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Abstract
Despite the advancements in biomarker-based personalized cancer therapy, the 
inadequacy of molecular and genetic profiling in identifying effective drug combi-
nations was defined in most cases. Drug resistance remains a major limitation of the 
current predictive oncology. Emerging reports indicate that the success of antican-
cer therapy is usually limited by intratumoral heterogeneity which is not captured 
by the existing cancer cell biomarker-based approaches. Cell heterogeneity, not 
only genetic but also phenotypic, is considered to be the root cause of resistance to 
anticancer treatment, cancer progression, and the presence of cancer stem cells. 
Therefore, functional testing of live cells representing various cell types within 
the tumor exposed to potential therapies is needed for identification of effective 
drug combinations. Here we look at the different existing model systems, includ-
ing ex vivo models of the patient’s tumor cells, 2D/3D in vitro cultures/cocultures, 
patient-derived cellular organoids, single-cell models, ex vivo tumor platforms 
containing tumor microenvironment and extracellular matrix, etc., scoping at drug 
efficacy evaluation and solving the problem of cancer resistance.
Keywords: ex vivo model, cancer heterogeneity, tumor microenvironment, cancer 
stem cells, anticancer therapy, drug resistance, plasticity
1. Introduction
Fighting cancer is a major challenge for scientists and clinicians. As a result of 
human population aging, today cancer is the most common cause of death in the 
world. One of the most promising measures to reduce cancer deaths is believed to 
be prevention. However, only smaller part of cancers can be prevented by avoiding 
environmental risk factors. The recent results presented in Science suggest that 
only one-third of the cancer risk is attributable to environmental factors or inher-
ited predispositions, and that unavoidable random errors or mutations (bad-luck 
mutations), occurring during DNA replication in normal stem cells, are a major 
contributing factor in cancer development [1]. Authors suggest that this stochastic 
factor is the major contributor to cancer overall. The results are consistent with 
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epidemiological estimates of the fraction of cancers that can be prevented by 
changes in the environment.
Therefore, random, replicative errors every time a cell divides can contribute to 
cancers all along tumorigenesis, and at the same time, environmental factors can 
play a role during all phases. Authors suggest two prevention strategies in cancer: 
primary and secondary [2].
The importance of spontaneous endogenously generated DNA damage in onco-
genesis is supported by the other recent studies [3, 4]. This understanding is vital 
for designing strategies to reduce deaths from cancer, suggesting the essential role 
of intervention. From that point of view, choosing the most effective medication 
and the treatment strategy as well as the ability to predict the treatment outcome is 
of particular importance.
Nowadays, biomarker-driven personalized cancer therapy has emerged as 
a powerful concept and significantly improved the results of cancer therapy. 
However, although discoveries in tumor genomics have led to the identification of 
a number of new cellular targets and the development of novel targeted drugs, cur-
rently available FDA-approved targeted therapies fall over time due to the develop-
ment of drug resistance after impressive initial response. Intrinsic and acquired 
resistances remain the major limitation of the current predictive oncology.
Data presented in Nature indicate that precision oncology strategy to target the 
specific mutations in a tumor (to link genetic testing of patients with the drugs that 
would work best for them) has not been shown to work well, and perhaps it never 
will [5–7]. Therefore, in addition to more targeted agents, there is a great need for 
new approaches and for more predictive model systems to substantially improve 
in vitro drug testing.
Emerging reports indicate that the success of anticancer therapy is usually 
limited by intratumoral heterogeneity which is not captured by the existing cancer 
cell biomarker-based approaches. Cell heterogeneity in the tumor is considered to 
be the root cause of resistance (both intrinsic and acquired) to anticancer treatment 
including conventional chemotherapy, radiation therapy, and molecularly targeted 
therapy. Traditionally, it is thought that it arises from distinct mutations in “driver” 
oncogenes; however, intratumoral heterogeneity depends not only on genetic 
modifications but also on nongenetic processes involving either stochastic events or 
epigenetic modifications [8].
The development of tumor cell heterogeneity is believed to be related to cancer 
stem cells (CSCs). Reversible transitions between CSCs and non-CSCs within the 
tumor contribute to intratumoral heterogeneity. The heterogeneity of cellular states 
in cancer has been linked to drug resistance, cancer progression, and the presence 
of cancer stem cells [9, 10]. Therefore, subpopulations of cancer cells can be mor-
phologically and/or functionally distinct, and this phenotypic diversity of cancer 
cells may account for differences in drug resistance. These data propose a different 
strategy in treating cancer by exploiting the observed phenotypic heterogeneity in 
cellular types.
Although current therapies rarely take intratumoral heterogeneity into account 
when predicting clinical response, the future oncology will likely require designing 
new innovative approaches involving ex vivo platforms that consider intratumoral 
heterogeneity in the context of therapy resistance mechanisms [11]. Detailed analy-
sis of the response of phenotypically different cancer cells to the applied drugs is 
required in each individual patient’s case. This analysis could be performed by using 
ex vivo patient-derived cancer cell lines and functional testing of different tumor 
cells exposed to potential therapies. Patient-derived models are needed to identify 
effective drug combinations for cancer treatment. New research, combining large-
scale molecular studies data from patients, laboratory cancer cell lines, and drug 
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sensitivity tests, showed that patient-derived cell lines did carry the same genetic 
alterations that drove cancer in patients, and thus are suitable to predict how tumor 
will respond to a drug [12]. This means that cell lines can be used to create tools for 
physicians to select the best available drugs for each patient individually. A reliable 
patient-specific model system, which includes patient’s ex vivo heterogeneous cancer 
cells as an experimental model, for the identification of effective drug combinations in 
individual cells in each individual cancer case should appear.
In any case, before running complex and expensive trials of individualized 
cancer treatment (including clinical trials, genetic, epigenetic, cellular, and immu-
nological research), studies involving the development of appropriate experimental 
cell culture models must be carried out. Only then the models can be used for the 
evaluation of cellular response of different tumor subpopulations to the chemother-
apy/targeted therapy treatment in every individual case, as well as for the identi-
fication of the best cell-type-specific treatment along with a proposed molecular 
mechanism and characteristic markers of the case.
Currently, various models are used for tumor resistance studies. Most popular 
methods are these: in vitro acquired resistance models using commercial cancer 
cell lines, while the other is searching for presumptive biomarkers. However, 
the first strategy does not reflect the actual situation of the individual patient, 
whereas the second strategy, without live cancer cells, lacks functional component. 
Experimental models of mouse tumors, including genetically modified mice and 
human tumor xenografts, due to large requirement of space, duration, and rela-
tively high price, are not very promising for use in the clinic. Also, these methods 
do not consider tumor cell heterogeneity. It is believed that cell-based functional 
studies and methods, once optimized, could bypass the need for whole animal 
cancer avatars [13].
Single-cell models (e.g., circulating tumor cells), being very promising for 
genomic, transcriptomic, and multiplex proteomic analyses, however, also have 
a disadvantage: functional studies in models of single cancer cells do not estimate 
the importance of extracellular interactions within a solid tumor, especially in 
response to the treatment [14]. Over the last few years, Science and other journals 
have published works on the use of patient-derived cell lines in the selection of 
targeted medicines in specific cases of resistant tumors, but cell subpopulations 
were not included in the studies [15, 16]. The most advanced model systems that 
contextually conserve the personalized tumor ecosystems, designed as a person-
alized ex vivo human cancer platform for the evaluation of the clinical response 
to the anticancer treatment—the CANScript and OncoCilAir—are a highly 
promising methodology that includes cell heterogenicity and tumor environment 
[17, 18]. The latter platform is new in vitro model of nonsmall cell lung cancer 
which combines a reconstituted human airway epithelium, human lung fibro-
blasts, and lung adenocarcinoma cell lines. These two are complex and expensive 
technologies and can emerge as a powerful platform for tailored cancer therapy. 
However, they do not evaluate the response of phenotypically different groups of 
cells to the treatment.
Until now, cellular in vitro technology has not been used in a clinic, but it is 
already in commercial use. According to BBC market research report, the global 
cell-based assays market was $ 15 billion in 2015 and is expected to reach over $ 28 
billion by 2021. In the treatment of cancer, researchers return to individual, disease-
determining cell research models (“Back-to-the-Future with Tumor Cell-Based 
Avatars”). There is no doubt that in the near future ex vivo models of tumor cells 
will be used in the clinic, and this would be an important step toward even more 
personalized cancer therapy. These approaches can be used to create tools for doc-
tors to identify the best therapies for individual cancer patients.
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Among these are the ex vivo models of the patient’s tumor cells having a dif-
ferent phenotype. With the help of new models, we hope the importance of tumor 
cell subpopulations will be justified in predicting the response to the treatment 
for a particular patient and, in a specific case, to identify possible therapeutic 
efficacy.
Optimization of these tests, verification, and evaluation of the costs of the most 
effective therapeutic solutions are necessary.
In this review, we will present the current ex vivo tumor cell models and clini-
cally relevant platforms to functionally test predicted drugs/drug combinations for 
individual patients.
2. Cancer genomics
Today, in the epoch of innovative technologies, a breakthrough in replacing 
conventional molecular diagnostics technologies with new ones such as next-
generation sequencing (NGS), has led to higher content analyses of cancer disease 
with improved cost-effectiveness and speed, higher sensitivity, and specificity [19]. 
It has enabled cancer biologists and clinicians to obtain valuable data of complex 
molecular alterations from clinical cancer patient samples rapidly. Based on this, 
The Cancer Genome Atlas (TCGA) (a collaboration between the National Cancer 
Institute and the National Human Genome Research Institute) has characterized 
diverse genomic alterations underlying individual human cancers by using over 
11,000 tumors from 33 cancer types. Multidimensional maps of key genomic 
changes in those tumors were generated, and systematic studies of these genetic 
changes were performed. Based on sequence and structure, 299 driver genes with 
>3400 putative missense driver mutations were identified with implications regard-
ing their anatomical sites and cancer/cell types [20]. In addition, comprehensive 
characterization of 10 selected signaling pathways was performed across the 33 
cancer types analyzed by TCGA. Alterations in those signaling pathways across 9125 
samples from 33 cancer types were determined. RTK/RAS/MAP-kinase and PI3K/
Akt signaling pathways, among others, were frequently found to be genetically 
altered in cancer [21]. Results from TCGA Pan Cancer Atlas project greatly deep-
ened the current understanding in various fields of oncogenesis such as somatic 
driver mutations, germline pathogenic variants and their interactions in the tumor, 
the influence of the tumor genome and epigenome on transcriptome and proteome, 
and the relationship between tumor and the microenvironment, including implica-
tions of prevention and treatment [22]. Based on recent genomic cancer research, 
new data are currently employed in the development of novel targeted drugs 
focusing on genes that are mutated in a tumor, e.g., activated oncogenes and their 
downstream signaling components [23].
At present, in the post-genomic era of the cancer therapeutics, the shift away 
from the use of conventional cytotoxic drugs toward molecularly targeted agents 
has occurred. Conventional chemotherapy is mostly directed at the majority of 
proliferating cells in tumors. Cancer is a genetic disease with genotypic changes 
that include: mutations, insertions, gene amplifications, deletions, gene fusions, 
chromosomal rearrangements, transposition of the genetic elements, transloca-
tions, and microRNA alterations. Detection of genetic alterations in specific regu-
latory molecules that are responsible for oncogenic transformation has enabled the 
development of targeted therapies [24, 25]. According to Hanahan and Weinberg, 
six hallmarks of cancer can be highlighted: sustained proliferative signaling; eva-
sion of growth-suppressive signaling, resistance to cell death; limitless replication; 
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induction of angiogenesis; invasion; and acquisition of metastatic capability. In a 
while, the same authors have emphasized additional cancer properties: deregula-
tion of cellular energetics, avoidance of immune destruction, genome instability, 
and tumor-promoting inflammation [26]. The phenomenon of “oncogene addic-
tion,” describing a special cancer cell dependency on a particular “driver” alteration 
for their survival, was defined in 2002 by Weinstein. In the last decade, the strategy 
to eliminate acquired genetic dependencies on oncogene addiction drivers by 
blocking them in each patient and in each tumor cell specifically has been widely 
translated into the clinic. Accordingly, the major classes of current US Food and 
Drug Administration (FDA)-approved targeted therapies include drugs that were 
designed to inhibit specific oncogenic mutations and molecular alterations specific 
to cancer cells, or aimed to increase the antitumor immune response, or inhibit-
ing neoangiogenesis. Additionally, beyond direct targeting of genomic defects, 
the process of differentiation, epigenetic alterations, and microenvironmental 
properties were taken into account in drug discovery. Novel treatments include 
advanced molecularly targeted therapies that may consist of cell-, hormone-, small 
molecule-, vaccine- or antibody-based therapies. They are tailored to inhibit signal 
transduction, regulate gene expression, induce apoptosis, diminish angiogenesis, 
and serve as an immunotherapeutic in specific cancers.
Individual genomic drivers are usually identified from the sequencing of the 
human genome. Molecular genotyping is now a customary practice applied to the 
cancer patients aiming to define their genetic profile. Consequently, genomic and 
other omics data are used to predict the drug sensitivity of an individual tumor 
[27, 28]. In parallel, a variety of molecularly targeted drugs are being studied 
in preclinical settings or clinical trials, and many targeted therapies have been 
approved by the FDA for treatment of different kinds of cancer. However, a range of 
drawbacks are monitored; for example, numerous drugs fail in early and late stages 
of clinical trials, partly due to insufficient drug efficacy. Before that, only 5–15% 
of investigational cancer drugs succeed in receiving clinical approval. Data suggest 
that new targeted drugs without proper stratification may reach only 10–20% effi-
cacy. In other words, only for a small fraction of patients, the genomics-driven can-
cer therapy can be very effective and improve the clinical outcome. However, for the 
rest, such therapy will not work. It is considered that 20,000 proteins are implicated 
and play key roles in cancer biology; however, today, a majority of these structural 
and regulatory classes of proteins appear to be undruggable. Alternatively, some 
identified targets have no drugs developed [23, 29, 30].
Although prolonged progression-free survival is monitored after successful 
targeted therapy, patients with cancer usually develop resistance to the drugs within 
6–12 months. As an example, in the case of lung adenocarcinoma, the initial clinical 
response to targeted drugs—protein kinase inhibitors—is almost always temporary 
due to acquired resistance [31]. In general, despite our increasing understanding 
of the molecular determinants of oncogenesis, many forms of the cancer remain 
incurable. Therefore, the complementary strategies to match their tumors to 
appropriate therapies are needed as genome profiling of tumors is insufficient to 
guide the therapy for most patients. Nowadays, molecularly guided therapy involves 
determination of DNA, RNA, proteins, metabolites, etc., as complementary 
biomarkers. Biomarker sets to detect individual and pathway drivers as molecular 
drug targets obtained from protein arrays, mouse avatars, and other models are also 
applied [24]. Among them, the application of proteomic technologies to study cell 
signaling networks, functionally important protein phosphorylation, and expres-
sion changes might play a key role in the discovery of both new biomarkers and new 
therapeutic targets [32].
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Nevertheless, it should be stressed that regardless of the mechanisms of the 
therapies, occurring resistance is a near-universal phenomenon in patients with 
cancer.
It is considered that genome-based cancer therapeutic matching is limited by 
incomplete biological understanding of the relationship between phenotype and 
cancer genotype. Even more, resistance does not necessarily depend on the cancer 
cell genotype. Although cancer is primarily a genetic disease and genetic muta-
tions are responsible for cancer initiation and progression, they are not necessarily 
responsible for the resistance to treatment and should not become the targets 
for therapy. In addition to more targeted agents, there is a great need for new 
approaches, more predictive model systems.
3. Cancer resistance
It is increasingly realized that cancer resistance occurs nearly in all patients 
regardless of the therapies used (targeted agents, chemotherapy or immunother-
apy). Anticancer drug resistance is a complex process. The cause of tumor resis-
tance could be both intrinsic and extrinsic and it develops through many different 
mechanisms.
Drug resistance can be categorized as primary (intrinsic) or secondary 
(acquired). Intrinsically resistant tumors do not respond to the therapy at all 
due to the resistance mutations which exist within cells prior to the treatment. 
Acquired resistance (post-therapy resistance) occurs due to selective propagation of 
pre-existing or de novo-induced molecular alterations after the anticancer therapy. 
Moreover, besides primary and acquired, authors name one more way for the 
resistance to arise. Adaptive resistance occurs due to cancer cell plasticity under 
the pressure of a drug, especially in the microenvironment which is throughout 
heterogenic. Further, acquired and adaptive resistance can also be subclassified as 
on-target or off-target.
Causative factors for cancer cell resistance are grouped into three categories: 
mutational events, non-mutational events, and changes in the surrounding micro-
environment. Genetic and nongenetic resistance mechanisms can act alone or in 
concert, in order to confer resistance to the applied therapy [27, 33]. Genetically 
caused acquired resistance involves emergence of de novo mutations in cancer cells. 
These mutations allow escaping the oncogene-targeted therapies by many ways. 
On-target resistance (alteration of the driver oncogene) occurs when the primary 
target of the drug itself gets altered. In this case, resistance occurs via a second-site, 
or secondary, mutation in the drug target. For example, under first generation 
EGFR TKI treatment, appearance of EGFR-T790M mutation is known as a second-
site mutation. Off-target resistance (activating mutations in other genes) occurs 
via activation of critical signaling molecules or pathways that are either parallel or 
downstream of the target. Upregulation of a distinct receptor tyrosine kinase is an 
example of such a bypass mechanism for TKI targeted therapy.
Downstream activation at the genetic level means that cancer cells can become 
resistant to targeted inhibitors by amplifying the target or acquiring activating 
mutations in signaling pathway genes downstream of the driver oncogene. In many 
cases, those are cell growth and survival-promoting pathways. An example of acti-
vation of downstream signaling is EGFR-driven tumors with resistant cells, which 
reactivate MAPK pathway at multiple downstream points by means of upregulated 
expression and/or enhanced activation of proteins in the EGFR/MAPK signaling 
pathway. Alternatively, activation of a new (parallel or surrogate) cell growth and 
survival-promoting signaling pathways beyond the oncogenic driver is another 
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escape mechanism for drug resistance. It can be exemplified that the inhibition of 
MAPK ERK signaling pathway molecules led to the activation of a parallel PI3K/
AKT/mTOR signaling pathway in lung cancer [27]. In general, various and different 
types of drug resistances have been shown in cancer cells. They involve activation of 
pro-growth and/or pro-survival signaling, cell death inhibiting pathways, altering 
drug targets as well as drug metabolism, enhancing DNA repair. Additional mecha-
nisms of resistance involve alteration in epigenetically regulated drug tolerance, 
gene expression, epithelial-to-mesenchymal transition (EMT), phenotypic trans-
formation, etc. [28]. Interplay between different signaling pathways, e.g., to induce 
adaptive activation of bypass signaling, was shown during acquired resistance.
3.1 Tumor heterogeneity
Accumulating evidence suggests that intratumoral heterogeneity plays an 
important role in cancer resistance to applied therapy, both conventional and 
targeted [9, 10]. Tumors are composed of heterogeneous cancer cell populations, 
either phenotypically or genetically different, and are marked by spatial and tem-
poral heterogeneity. Even after malignant transformation, cancer cell clones remain 
dynamic and continue accumulating mutations. This ongoing evolution ultimately 
generates distinct molecular signatures in different loci of a tumor. Intratumoral 
heterogeneity itself may be responsible for the evolution of cancers as well as for 
differential levels of sensitivity to treatment. Various drug-resistant clones with 
different properties appear within the tumor tissue both prior and after the cancer 
therapy. Importantly, cellular composition of a tumor can change substantially over 
the time [31, 33, 34]. In that respect, the combination of different approaches—one 
targeting pathways and alterations implicated in resistance of different tumor 
composing cells and the other directed to overcome heterogeneity—is a promising 
strategy in cancer treatment.
Causes of intratumoral heterogeneity may be intrinsic or extrinsic and genom-
ics or phenotypic. Among intrinsic factors, genomic instability is critical for the 
development of intercellular genetic heterogeneity in cancer. Genomic instability 
along to cell-to-cell variation leads to acquired resistance. Extrinsic factors include 
pH, hypoxia, paracrine signaling, interactions with stromal and other tumor cells, 
surrounding matrix as well as other environmental influences. Genetic alterations 
might be caused by exogenous mutagenic factors (UV radiation, tobacco smoke) or 
endogenous defective processes such as errors during DNA replication, repair, etc. 
Meanwhile, phenotypic diversity can reflect differences in cell cycle stage, stochas-
tic phenotypic alterations, or hierarchical position during development. Primary 
genotypic or phenotypic variations prior to therapy also describe intratumoral 
heterogeneity in many tumors. Therefore, temporal-spatial differences between 
distinctive subpopulations of tumor cells within the same tumor at both genetic and 
epigenetic levels cause tumor heterogeneity [34].
Various models have been proposed to explain intratumoral heterogeneity.
The clonal evolution model postulates that somatic mutations stochastically 
occur in various clones within the tumor at different sites and different disease 
stages, leading to differential growth patterns and resulting in spatial-temporal 
tumor heterogeneity. In clonal evolution model (linear or branched) genetic muta-
tions gained by tumor cells contribute to their altered phenotype and differences in 
resistance. Those differences in the biological properties are inherited by individual 
cancer cells clones. In this way, genomic instability leads to cell-to-cell variation as 
well as acquired resistance.
In the model of stem cells, clonal expansion of slow cycling cells, displaying 
stem cell-like behavior (self-renewal and differentiation capability), leads to tumor 
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heterogeneity [34]. The role of cancer stem cells (CSC) in determining heterogene-
ity and resistance in cancer will be described below.
One more theory, the so-called phenotypic plasticity model, suggests that cancer 
cells are capable of switching between different transcriptional programs, and 
therefore, phenotypic and histological transformation occurs. In this model, unlike 
the clonal evolution and stem cell theories, reversible molecular changes result in 
tumor heterogeneity. Inconsistent drug responses between cancer cells can be a 
result of diversification of epigenomic, transcriptomic, proteomic, metabolic, and 
functional states driven by tumor cell microenvironment changes [8, 29, 35, 36].
One of the mechanisms of phenotypic change is via EMT, an evolutionarily con-
served program of transdifferentiation. EMT is observed clinically in patients with 
acquired resistance.
Lastly, another mechanism of cancer cell evolution was described. Briefly, 
there are proofs that cancer cells fuse with fibroblastic or mesenchymal cells to 
produce genetic hybrids with enhanced malignant profile both in vivo and in vitro 
[37]. Taken together, all these models in concert explain all the attributes of tumor 
tissue heterogeneity as well as genetic cell-to-cell variation and acquired resistance. 
Indeed, the findings of multiple studies demonstrate that a combination of genetic, 
epigenetic, and functional mechanisms contributes to intratumoral heterogeneity 
with different levels of sensitivity to anticancer therapies. Moreover, heterogeneity 
is dynamically changing over time and in concert with changes in therapy [33]. 
Heterogeneity of cellular states in cancer has been linked to drug resistance, cancer 
progression, and the presence of cancer stem cells [9, 10].
3.2 Cancer stem cells
An important role in the development of cancer heterogeneity is attributed to 
CSCs. In this model, tumor heterogeneity is determined by CSCs existing at differ-
ent levels of hierarchical tree and possessing different phenotypes. CSCs are present 
in almost all cancers as a small population of drug-resistant, tumor-initiating cells 
and make up less than 1% of the tumor cell population. Recent data show that dur-
ing cancer progression, gradual loss of a differentiated phenotype and acquisition 
of progenitor and stem cell-like features are observed. Cells with dedifferentiated 
phenotype were mostly prominent in metastasis [38, 39].
Different factors are recognized as causes of CSC emergence. It can be cell 
fusion, horizontal gene transfer, and mutations in somatic or differentiated cancer 
cells, ultimately resulting in their dedifferentiation and reprogramming. Mutations 
leading to the aberrant regulation of a majority of stemness and proliferation 
pathways distinguish CSCs from non-CSCs residing within the tumor. In response 
to various factors such as wounding, stress, or hypoxia, a differentiated cancer cell 
can dedifferentiate into a CSC. Reversible transitions between CSCs and non-CSCs 
within the tumor contribute to intratumoral heterogeneity [40, 41].
Incidences of different oncogenic rearrangements in stem, progenitor, or 
mature cells can lead to the generation of CSCs too. Authors propose that breast 
cancer CSCs could have been generated from adult somatic cells, through acquired 
mutations responsible for uncontrolled reactivation of pluripotency-associated 
programs. Deregulated canonical and developmental signaling pathways are highly 
associated with CSC phenotype and regulation of CSC behavior. Alterations in 
proliferation, differentiation, and programmed cell death pathways have been 
demonstrated [42].
It is believed that CSCs are a quiescent, low-cycling cell population. Another 
specific property of CSCs is resistance to chemotherapeutic drugs. Self-renewal and 
cellular quiescence characterize both normal adult stem cells and CSCs; they also 
9Recent Approaches Encompassing the Phenotypic Cell Heterogeneity for Anticancer Drug…
DOI: http://dx.doi.org/10.5772/intechopen.89395
can divide asymmetrically and are able to produce progenies of multilineage differ-
entiation. CSCs are regulated by similar cell signaling pathways and express similar 
cell-surface and intracellular markers as normal stem cell. Growth factor TGF-β, 
signaling pathways FGFR/MAPK or Akt, Wnt, Notch, and Hh, and major transcrip-
tion factors Oct3/4, SOX2, and Nanog are involved in maintaining self-renewal and 
pluripotency of CSCs as well as of embryonic stem cells.
Many markers have been associated with the CSC phenotype; however, no uni-
versal CSCs markers were found, suggesting the existence of heterogeneous CSC 
populations within a heterogeneous tumor [38]. Indeed, CSCs are both genetically 
and phenotypically heterogeneous. CSC plasticity is the major determinant of 
their intratumoral heterogeneity. Dysregulation of key effectors in the above-
mentioned signaling pathways modulate CSC properties [34]. Recent research has 
emphasized extensive metabolic variability in CSCs—each distinct CSC popula-
tion possessed a unique metabolic profile. Both intrinsic factors (genetic and 
epigenetic alterations) and extrinsic factors (mainly tumor microenvironment) 
were shown to be implicated in the regulation plasticity as well as in maintain-
ing stemness. Signaling molecules of Wnt, Hh, and Notch pathways, along with 
metabolic regulators such as HIF1α, maintained CSC populations within tumors 
[34, 38]. Even more, increasing data show that cells with self-renewal potential can 
be generated from terminally differentiated somatic cells, thus reverting hierarchi-
cal developmental organization. For example, there is evidence that breast CSCs 
have originated from non-stem cancer cells [42]. Under the regulation of multiple 
factors, differentiated cancer cells could regain “stemness,” in this way confirm-
ing bidirectional conversion between non-stem and stem cells [34]. In that case, 
transformation of “non-stem cell to stem cell” contributes to the development of 
the heterogeneity within a tumor.
Core signaling pathways that regulate the phenotype of normal stem cells are 
responsible for dedifferentiation and acquisition of stem cell features in a tumor 
when transcriptionally and epigenetically deregulated. There are data that CSCs are 
maintained in the undifferentiated state through extrinsically regulated epigenetic 
mechanisms [39]. Therefore, CSCs may be considered as a status rather than a fixed 
subset of cancer cells. Transformation between modes of non-stem cells to stem 
cells or vice versa contributes to the development of heterogeneity within tumor.
The studies of last decades have shown a link between cancer stem cell forma-
tion and the process of epithelial-mesenchymal transition. This connection might 
be responsible for tumor heterogeneity, progression, and acquired resistance 
to therapy, followed by disease recurrence [40, 41, 43]. Namely, epithelial cells 
undergoing EMT acquire CSC phenotype and chemoresistance. Moreover, these 
cells may go back and forth along this transition. As described in a breast cancer 
study, two distinct populations (epithelial-to-mesenchymal and mesenchymal-to-
epithelial) of CSCs were found [44]. Current data indicate that CSCs are not fixed 
at full epithelial or full mesenchymal cell status, but maintain plasticity between 
EMT and MET states [42, 45]. Consequently, tumors are supposed to consist of 
continuous sequence of cell states along epithelial to mesenchymal positions [46]. 
Also, non-stem cancer cells were shown to regain stemness through an epithelial-to-
mesenchymal transition-mediated process [38].
Processes of EMT are regulated in response to the environmental changes and 
involve canonical and developmental signaling pathways that induce the expression 
of transcription factors, referred as “master regulators” of EMT, as well as epigen-
etic and post-translational regulators. Those include members of the Snail and ZEB 
transcription factor families. Different signaling pathways, e.g., Wnt/β-catenin 
pathway or AKT/STAT3, contribute to EMT [47–49]. Although it is widely accepted 
to link stemness to the EMT, there is another view proposing that these processes 
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occur in parallel rather than through the same pathway [38]. Regardless, a wide 
spectrum of hybrid epithelial/mesenchymal (E/M) cellular states which combine 
epithelial and mesenchymal features are formed during epithelial-mesenchymal 
transition.
It is increasingly understood that cell plasticity in the tumor can affect treat-
ment outcomes. EMT grants resistance to cell death induced by different agents, 
including conventional, targeted, and immunological, in cancer cells. Different 
phenotypes of cancer cells may confer changes to both sensitivity and intracellular 
regulation of cellular biology; different signaling may be acquired in response to 
one treatment. There are data about it in various cellular and preclinical models; 
however, more data from clinical cases are needed [50–54].
As discussed above, drug resistance is a specific property of a CSC. It involves 
various aspects of CSC functioning and is mediated by multiple mechanisms, 
such as: ATP-dependent ABC transporter-mediated drug efflux; inactivation of 
anticancer drugs; changing the targets of chemotherapeutic agents; slow cell cycle/
quiescence; self-renewal property and stemness-regulating signaling; disrupted 
differentiation; metabolic modulation; antiapoptotic measures (upregulation of 
antiapoptotic and downregulation of proapoptotic genes); improved DNA damage 
response; epigenetic alterations (DNA methylation, histone alterations, microR-
NAs); immune escape mechanisms; etc. [34, 38].
Based on the abovenamed features and mechanisms of CSC resistance, differ-
ent strategies to tackle CSC resistance were developed, mainly focusing on CSC 
elimination or induction of their differentiation. More than 60 CSC-targeted 
reagents have been registered for clinical trials (e.g., Reparixin, Demcizumab, 
Napabucasin, metformin, etc.) [55]. However, to our current knowledge, there are 
no drug discovery platforms that would include EMT reversal and overcoming its 
conferred resistance. Nevertheless, the results from TCGA project encourage stem-
ness signatures were found, and certain inhibitors were proposed as potential drugs 
for various cancers [39].
3.3 Tumor microenvironment
Development of drug resistance in cancer, regardless of mechanism, is highly 
dependent on the tumor microenvironment [35]. Tumor microenvironment 
includes the cells composing tumor stroma (normal fibroblasts, cancer-associated 
fibroblasts (CAFs), vascular endothelial cells, infiltrating immune cells, etc.), 
soluble molecules, and the extracellular matrix (ECM). Other factors of tumor sur-
roundings, such as availability of nutrients and oxygen, and biophysical properties 
of the extracellular matrix are also important factors in regulating tumor cell behav-
ior. Cancer cell interaction with stroma cells, with other cancerous cells, and with 
ECM contribute to direct cell interaction-mediated drug resistance known as tumor 
cell interaction-/adhesion-mediated resistance. Probably the best-known example is 
the CAFs. Those specific cells are most abundant cells in the tumor stroma responsi-
ble for the buildup and remodeling of the tumor microenvironment. CAFs produce 
ECM components such as collagens (I, III, IV, and V), hyaluronic acid, fibronectins, 
and laminins; alternatively, they secrete matrix metalloproteinases. Cancer-
associated fibroblasts possess high expression of α-SMA, CD44, HI-1α, MMP11, 
VEGF, CXCL12, TGF-β1, TGF-βRII, IL6, and TNFα biomarkers. In many studies, 
such cells were demonstrated to be involved in cancer progression and resistance to 
therapy [56–59]. As an example, it was demonstrated that functional and proliferat-
ing colon cancer stem cells that ensured tumor expansion predominantly resided 
at the tumor edge close to cancer-associated fibroblasts [60]. Furthermore, factors 
secreted by cancer cells and acting through autocrine mechanisms are involved in 
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protection of cancer cells against treatments; that is called soluble factor-mediated 
drug resistance. Various cancer cell-released molecules are known as contributors to 
chemoresistance; it can be growth factors, glycoproteins, inflammatory cytokines, 
enzymes, chaperones, tumor-derived exosomes, etc. [61]. As an example, the recent 
study highlighted that cancer-associated fibroblasts induced ovarian cancer cell 
chemoresistance in transmanner by secretion of CCL2/CCL5 and induction of IL-6 
production [62]. Microenvironment-driven dynamic heterogeneity and phenotypic 
plasticity was recognized as mechanisms of therapy resistance in melanoma [35]. 
Hence, development of drug resistance in cancer, regardless of a mechanism, is 
highly dependent on the tumor microenvironment. Moreover, factors secreted by 
tumor cells themselves or by the cells of its microenvironment play a crucial role 
in the development of epithelial-mesenchymal transition at the invasive front of 
primary tumors. Paracrine and autocrine mechanisms of EMT induction in cancer 
are evidenced in literature and may include exosomes or free proteins and miRNAs 
[63]. Consequently, distinct subpopulations of cancer cells with distinctive biologi-
cal features appear in the tumor and thus respond differently to the therapy.
The critical role of tumor microenvironment, which is composed of cellular 
and noncellular components in cancer development and progression, is evident. 
As EMT is considered to be one of the key factors in progression of tumors to 
malignancy [64, 65], the role of ECM in this process was demonstrated. ECM 
composition was partially responsible for insufficient therapy and appearance 
of heterogenic cell populations, which were characterized by different response/
susceptibility to anticancer agent [66]. Dynamic nature of ECM regulates behavior 
of cancer cells by triggering signaling pathways through adhesion proteins like 
integrins [67]. Collagen I, which is the major component of extracellular matrix, 
has been shown to support phenotypic changes of cancer cells [68]. Studies 
conducted on 3D tumor-ECM in vitro cancer models demonstrated importance of 
ECM composition and stiffness on this transition regulation [69, 70]. On the other 
hand, noncellular components of ECM, e.g., proteins, glycoproteins, and pro-
teoglycans, form a physical barrier for penetrating drug. Numerous cell-cell and 
cell-ECM contacts attenuate penetration of drug molecules into different layers of 
tumor [71, 72].
4. Models of cancer treatment prediction
Today, a lot of conferences addressed to advancing drug discovery, cancer 
pharmacology, and tumor modeling are held worldwide, e.g., Predict Tumor 
Models (London, UK, 2017; Boston, MA, 2019), 3D-Oncology (Boston, MA, 2019), 
EACR Goodbye Flat Biology (Berlin, DE, 2019), and SelectBio 3D-Culture and 
Organoids/Organ-on-a-Chip World Congress (San Diego, CA, 2019). Realization 
that new approaches in oncology are necessary to improve cancer treatment is 
increasing. The topics in such conferences include: How to satisfy the demand for 
clinically relevant models for understanding disease progression; Multicellular 
interactions and the immune microenvironment; Advancing 3D-based models for 
cancer biology and drug discovery; Influence of microenvironment on stemness; 
Microenvironment and metabolic regulation of cancer invasion; Highlighting 
the pitfalls of complex approaches with regards to cost, speed and accuracy; The 
true utility and translatability of 3D tumor models within drug research; etc. 
Likewise, big pharma companies and small start-ups are offering nonconventional, 
patient-specific and often patent-protected cancer models, desirably reflecting the 
complex nature of tumor microenvironment and cell heterogeneity. For example, 
Champions Personalized TumorGrafts™ have offered patients and physicians using 
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their in vivo xenograft mouse avatar-based diagnostic model at a cost of approx. 
$10,000 [73]. The demand for cancer models that reliably mimic the intrinsic 
ecosystem of a solid tumor in vivo is really high. However, to create and replicate a 
system consisting of malignant cells, normal and abnormal stroma, immune cells, 
as well as dynamic microenvironment containing gasses and nutrients, chemokines, 
cytokines, growth factors, together with specific extracellular matrix, is totally 
challenging [74, 75]. In addition, clinical application of such models may become 
reality only if the patient benefit justifies the cost of the methodology.
The use of reliable in vitro cell model, which precisely reflects the situation 
in vivo is critically important during preclinical drug studies. Due to the high 
mortality from cancer, the search of new and more effective anticancer agents still 
remains a highly challenging area of biomedical research. The principle of targeted 
cancer therapy is based on biochemical differences between cancer and healthy 
cells. In regard to low efficacy of drugs passed through Phase II and III of clinical 
studies and acquired resistance of tumor cells to therapy, more detailed studies 
of tumor structure, histology, and biology are required. These fields remain very 
important since a choice of inadequate in vitro drug screening system further 
results in low efficacy or high toxicity of anticancer agent during clinical studies 
[76, 77]. Advances made in cancer research in the last decades demonstrate critical 
role of tumor microenvironment in cancer development, progression, and response 
to therapy. According to different studies, potent anticancer drugs that demon-
strated high efficacy in 2D cancer cell cultures had significantly reduced effective-
ness during further studies in vivo [78]. In human body, tumor represents a highly 
complex architecture that is difficult to replicate in vitro. First of all, it is highly 
heterogenic multilayer structure, formed by different type of cells, e.g., cancer 
cells, cancer-associated fibroblasts, tumor infiltrated endothelial cells, and cells of 
immune system. Cellular components of tumor regulate different features of cancer 
cells such as proliferation, invasiveness, and susceptibility to drugs [79]. Tumor 
represents a mixture of genetically, epigenetically, and phenotypically different 
populations of transformed cells. Elimination of all viable cancer cells which are in 
different status makes it very challenging to target particular molecular drivers of 
cancer. It is known as well that cell heterogeneity is increasing with disease progres-
sion. Thus, even modern targeted therapy becomes insufficient in some cases of 
cancer [80–82].
Failure to advance in cancer therapy has been attributed to the complexity of 
the disease. A solid tumor is often called “an organ” but very heterogenic and of 
irregular structure with many niches and different conditions inside. Today, there is 
a gap between scientific understanding of tumor complexity and concrete measures 
to fight cancer in clinics. This gap is constantly being filled with preclinical cancer 
models, but up to date, no model, at the same time, is fast, accurate, affordable, and 
suitable for clinics.
One of the hypotheses to explain cancer resistance to therapy is cancer stem 
cells, or cancer-initiating cells. Although they are more recognized as a phenotypic 
status or mode rather than a fixed subset of cancer cells, various authors distinguish 
certain populations of cells within a tumor that propagate cancer [83–87]. The main 
trick regarding those cells is that when they are asleep, they evade chemotherapy; 
when they wake up, they cause cancer recurrence. Killing those cells selectively is a 
priority [9]. Other authors propose that cancer genome undergoes clonal evolution 
under the pressure of constant stress and after cancer therapy. One study compared 
the genomes of 100 early stage resected lung tumors and found driver mutations 
in EGFR, MET, BRAF, and TP53 are almost always clonal; moreover, cells from 
different parts of the same tumor had very heterogenic genomes [88]. Accordingly, 
every single case of cancer is very individual and may be genetically and in other 
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ways substantially different. Noncellular components of tumor environment such 
as secreted grow factors, RNA and DNA molecules, metabolites, and extracellular 
matrix proteins regulate various biological functions of cancer cells [71]. Therefore, 
commonly used purified cancer cell lines in vitro do not possess the heterogeneity, 
nor genetic nor phenotypic, and thus may represent only a small fraction of this 
multiplexed pathology [89]. Even when heterogenic and in an enriched medium, 
2D cell cultures lack the architecture and complexity of a real tumor and thus are 
not suitable for cancer biology and immunology studies [90]. However, ordinary 
cancer cell cultures on flat plastic are successfully used in fundamental research.
Trying to describe cancer cells in molecular signature led to the emergence of 
“biomarkers”—certain molecules that are specific to cancer cells. Although this 
goal is not ultimately achieved yet, many cancer biomarkers are used in cell profil-
ing, cancer research, and targeted drug development. For example, in a search for 
cancer stem cells in lung cancer, CD44, CD133, and CD90 had been considered as 
potential biomarkers, but CD44 showed the best specificity in one study [91], and 
CD133+CXCR4 in another study [92]. In pancreatic cancer, co-expression of CD24, 
CD44, EpCAM, and CD133 corresponded to more aggressive cell behavior [93]. As 
we have described above, an initiative called The Cancer Genome Atlas (TCGA) 
has generated comprehensive, multidimensional maps of key genomic changes 
in 33 types of cancer in order to investigate somatic driver mutations, germline 
pathogenic variants, and their interactions in the tumor, the influence of the tumor 
genome and epigenome on transcriptome and proteome, and the relationship 
between tumor and the microenvironment, including implications of prevention 
and treatment [22]. On its basis, other authors have performed analysis by using 
26 computational tools and identified 299 driver genes [20] as well as alterations in 
signal transduction [21]. It is worth mentioning that DNA sequencing is becoming 
part of routine clinical care that may result in rapid and high-throughput analysis of 
complex germline and somatic alterations from clinical cancer patient samples [19].
Probably more complex and more ambitious project has been started in 2017—
The Human Cell Atlas. Such atlas is believed not only to append new cell types of 
a human body to the known ones but also to help scientists to track cell lineage, 
dynamic states, and stemness of cells as well as communication between cells. 
This database may include not only genomic and transcriptomic data from a single 
cell, but also profiling the accessibility of the chromatin [94]. It is really important 
to investigate cells one by one for many reasons when talking about cancer. For 
example, conversion to stem-cell state in response to microenvironmental cues was 
regulated by balance between epithelial and mesenchymal regulators (described by 
expression of CDH1 and SNAI2, respectively) in lung cancer cells [95].
4.1 In vivo models
Human tumors can be grafted into immunodeficient mice to generate so-called 
patient-derived xenograft (PDX) mice. PDX is a powerful tool aiming to test 
multiple drugs or drug regimens. It is considered as a preferred option in cancer 
research as it mimics the native features of tumors more closely compared to con-
ventional cell culture drug screening platforms. With its drawbacks as a system, it 
is still important, widely used, and remains a gold standard for preclinical develop-
ment and individual drug discovery.
Different PDX repositories exist that represent models of various tumors. Conte 
and colleagues try to accumulate the data into one comprehensive open global cata-
log of PDX models and their associated datasets that would ease the identification 
of PDX models relevant to specific cancer research questions [96]. The standard 
was also developed to unify generation, quality assurance, and use of PDX models, 
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because the processes of creation and characterization of PDX models considerably 
differed among institutions [97].
Beyond PDX mouse model libraries, now patients can be offered individualized 
mice, which is a platform used for the measurement of efficacy of experimental 
treatments exploiting patient’s own malignant cells. The aim is to have a model 
with experimental data as close as possible to human disease situation. Individual 
approach is vital here as cancer is the most genetically diverse and unique disease 
with different genetic alterations existing between individual patients, individual 
tumors, and even within a single tumor.
In PDX model, a patient tumor specimen is directly transplanted into immu-
nocompromised mice. This allows representing critical molecular and biological 
properties of the original tumor, and immunodeficient mice prevent graft rejec-
tion. Several types of such mice are used for PDX generation. Currently, the most 
commonly used types of immunodeficient mice are nude, severe combined immu-
nodeficiency (SCID), and nonobese diabetic (NOD) SCID γ (NSG). The latter is 
the most severely immunodeficient due to the lack of T, B, and NK cells [98]. NSG 
engrafting success rate is higher compared with that of in nude and NOD/SCID 
mice; therefore, NSG mice are considered the most suitable ones for the efficient 
engraftment of human tumor.
Tumor tissue fragments or single-cell suspension is used for PDX establishment, 
and both have their advantages and disadvantages. Tumor fragments preserve cell-
cell interactions and tissue architecture of the tumor, and all this mirrors the tumor 
microenvironment. However, a fragment does not represent the whole tumor, 
unlike single-cell suspension that helps to avoid tumor subclones. One can distin-
guish an additional PDX model that also recapitulates the molecular heterogeneity 
of the corresponding tumor and can be used to study cancer biology—circulating 
tumor cells (CTCs). These are released from cancerous lesion into peripheral blood 
and may infiltrate distant tissues inducing metastasis. CTCs represent a method for 
liquid biopsy which is used to generate various CTC-derived preclinical models.
Tumor fragment can be implanted heterotopically, that is, into the area unre-
lated to the original tumor site (usually subcutaneously). A major disadvantage 
of heterotopic implantation is that microenvironment of the subcutaneous space 
differs greatly from that of the original organ. Thus, orthotopic transplant models 
have been developed in which tumor fragment is directly implanted into the cor-
responding anatomical organ. Orthotopic PDX is considered an exemplary one as 
unlike subcutaneous model it mimics primary tumor’s natural environment that 
enables relevant tissue-related gene expression. In some cases, it reflects responses 
to therapy more closely than heterotopic PDX. Consequently, orthotopic models 
may be better predictors of therapeutic response [99]. Besides, subcutaneous model 
rarely produce metastasis [100], while orthotopic PDX is more likely to metas-
tasize [101]. However, orthotopic PDX generation is technically demanding and 
tumor changes have to be monitored via expensive and laborious imaging process. 
Therefore, subcutaneous models are currently preferred for preclinical studies.
Tumor engraftment is a critical milestone in PDX generation. Time from tumor 
sample implantation to progressive growth may range greatly. Authors provide 
different timeframes for PDX generation or tumor graft latency ranging from 2 to 
12 months [102–104]. The differences in time and engraftment rate are determined 
by tumor characteristics, like aggressiveness, histological type, and tumor cell 
percentage in the tissue [105]. Prasetyanti and colleagues showed that tumor cell 
proliferation was associated with successful PDX establishment and as one would 
expect this allowed to distinguish patients with poor clinical outcomes [106]. The 
others report the ability of NSCLC to grow as xenograft in mice as an accurate indi-
cator of poor prognosis for patient survival [107, 108]. Similar data were received 
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with breast cancer [109] and head and neck squamous cell carcinoma (HNSCC) 
models [110]. Here, authors claimed that the clinical application of rapid engraft-
ment as a biomarker for risk stratification could potentially improve the outcome 
of patients. Despite the wide array of PDXs generated for different tumors, some 
cancers, e.g., prostate, luminal ER+ breast, and neuroendocrine, remain under-
represented [111].
Tumor implant location is another important factor for successful engraftment. 
It was shown that tumors had higher success rates grafted in subrenal capsular sites 
[107, 112] due to better blood supply. The strain of immunodeficient mice used for 
engraftment also plays its role. Not surprisingly, engrafting success rate in NSG 
mice is increased compared to other strains.
After harvesting the tumor, it can be cryopreserved, characterized, or dissected 
again for reimplantation and propagation into other mice. This allows to expand 
PDX from one biopsy into multiple mice and to receive numerous data points from 
the same original tumor.
PDX retains tumor architecture and microenvironment with physiological 
conditions reflecting original tumor. Grafted tumor tissue maintains the genetic 
and epigenetic changes found in the patient, and also it retains patient’s stroma 
[113, 114]. PDX mice models can preserve tumor heterogeneity at least in early 
passages. They retain heterogenous molecular pathways of drug resistance that 
exist in tumor or in the cells comprising tumor environment [115]. As these models 
retain the biological characteristics of the donor tumors, they become indispensable 
for drug safety and efficacy research in preclinical studies as well as in co-clinical 
trials. These models are also exploited to examine personalized treatment strate-
gies—response to antitumor therapeutics and identification of the mechanisms of 
resistance that can be primary or acquired [116–118]. PDXs may represent intratu-
moral and intrametastatic heterogeneity and, therefore, more accurately predict 
mechanisms of resistance to clinical treatments [119].
Mice PDX models from various kinds of tumors have been established to study 
tumor biology, drug screening, and biomarker discovery. Authors report PDX gen-
erated for nonsmall cell lung carcinoma closely mimics the characteristics of patient 
primary tumors [120, 121], lung squamous cell carcinoma [122], and colorectal 
cancer [123]. Data are also available for renal cell carcinoma [124], melanoma [125], 
gastric [126], breast [127], and other cancers.
Data show that PDXs have a predictive power in clinical therapy outcomes since 
drug activity in PDXs phenomenally correlates with patient’s clinical outcome. 
In 112 out of 129 therapeutic outcomes, a remarkable correlation was observed 
between drug responses in patients and the corresponding PDX models of various 
solid tumors. Data showed that PDXs reproduced patients’ clinical outcomes, even 
in cases when patients underwent several additional cycles of therapy over the time. 
This indicates the potential of these models to provide the guidance on treatments 
[128]. More data with PDX models of breast cancer and lung adenocarcinoma 
origin confirmed high rate of consistency in patient and relevant PDXs [129, 130]. 
In addition to that, PDX models of colorectal cancers treated with EGFR inhibitor 
showed response rates like those of the patient [131]. Gu et al. evaluated the cor-
relations between PDX model-based mouse trials and cancer patient-based clinical 
trials. Results disclosed a high correlation in the rates of RECIST criteria between 
mouse trials and Phase II and III studies [132]. Research with pancreatic cancer PDX 
revealed that metformin treatment did not inhibit the growth of pancreatic can-
cer; clinical trial echoed PDX data—there was no benefit of adding metformin to 
combination therapy [133]. Eventually, in renal cell cancer model, correlation was 
noticed between PDX and clinical results in responses to Sirolimus, Sunitinib, and 
Dovitinib, but not Erlotinib [134].
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Correlation between PDX models and clinical trials also allowed discovery of 
biomarkers for drug susceptibility and resistance. Vemurafenib-resistant melanoma 
model was generated using PDX. Resistant tumors showed reliance on BRAF signal-
ing due to the elevated BRAF (V600E) expression [135]. Accordingly, elevated 
BRAF expression could be a potential biomarker for Vemurafenib resistance. The 
other data showed relationship between Gemcitabine resistance and survival of 
pancreatic cells with deoxycytidine kinase activity [136].
Co-clinical trials are parallel studies with mouse PDX models and patients. 
PDX model is established from the patient participating in a study, and the same 
treatment is applied to patient and PDX [116]. On the other hand, PDX model can 
be treated not only with the same drug that is used in the donor patient, but also 
with other drugs or drug combinations. This concept integrates preclinical and 
clinical data and facilitates the selection of an individual treatment to the patient. 
In addition, screening for prognostic biomarkers can be conducted, and drug 
response as well as resistance mechanisms can be investigated [137]. Usually, with 
the progression of cancer, the drug becomes less effective partially due to appear-
ance of resistance mechanisms. During a clinical study, it is not possible to reveal 
timing and mechanism of resistance. Here, PDXs are also of use allowing to predict 
both the development of resistance to the first-line therapy as well as the response 
to second-line therapy before this is observed in the donor patient, and to adjust 
further treatment accordingly [138]. Authors report correlation between clinical 
results and PDX models. Kim et al. conducted co-clinical trial to identify predictive 
biomarkers for the multikinase inhibitor Dovitinib in lung squamous cell carcinoma 
(LSCC) and revealed that FGFR gene expression signatures were predictors for the 
response to Dovitinib in LSCC [139]. Stebbing et al. provided data that supported 
the use of the personalized TumorGraft model as an investigational platform for 
therapeutic decision-making that could guide treatment for rare tumors such as 
sarcomas [140]. Others showed that PDXs reliably replicated clinical outcome in a 
Phase II co-clinical study of arsenic trioxide in relapsed small-cell lung cancer [141].
Currently, there are no much data, however co-clinical trials should find their 
place in the future as they give possibility to evaluate the efficacies of several drugs 
or drug combinations, save time, and reflect personalized medicine. However, while 
aforementioned advancements have been made in PDX applications, these models 
still retain some important limitations that should be noted.
Several practical challenges are related to PDX models. First of all, it is important 
to transplant the representative tissue, which is a matter of concern when it comes 
to larger tumors. Those tumors that have genetic heterogeneity cannot always be 
recapitulated in serial passages if the genetic heterogeneity is not all represented in 
the dissected tumor that is passaged [142]. Also, the best transplantation strategy 
should be chosen for specific tumor type. Orthotopic transplantation is considered 
more suitable; however, it is more complex and special surgical technique is neces-
sary. Consequently, more time and labor are required for model establishment. 
Engraftment failures are also to be discussed as percentage is still low in some tumor 
types. It is known that clinically aggressive tumors with many proliferative cancer 
cells have the highest engraftment rate [143]. Studies in which PDX models had 
been created simultaneously from primary and metastatic tumors proposed that 
metastases had a higher engraftment rate [144].
The other limitation of PDX system is the substitution of human stroma with 
murine components that occurs over the time with repeated passages. Human 
stromal elements are maintained for only 2–3 passages [111]. Later, the interaction 
of human cells with the murine microenvironment changes cell functioning and 
characteristics due to interspecies incompatibility, and the heterogeneity of exact 
human tumor microenvironment might not be retained. Therefore, therapeutic 
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studies are more representative in low-passage models. To reduce the influence of 
murine stroma on the PDX model, co-engraftment of human mesenchymal stem 
cells or cancer-associated fibroblast cell lines in PDXs is explored. One promising 
approach is the isolation and co-engraftment of patient-derived fibroblasts [145].
How cancer emerges and develops depends on its interaction with the host 
immune system. In addition, cancer response to therapy is also determined by pre-
existing immune phenotype; it also depends on immune system responses caused 
by drug introduction [146]. Lately, several cancer immunotherapies have been 
evaluated in preclinical and clinical studies. However, standard PDX models were 
inconvenient for the analysis of tumor immunology and immuno-oncology drugs 
(e.g., immune checkpoint inhibitors) as the immunodeficient mice had no cytotoxic 
T cells. To overcome this problem, humanized PDX models have been developed 
using injection of peripheral blood lymphocytes or tumor-infiltrating lymphocytes 
into NSG mice [138]. But this did not resolve the issue in general, as after several 
weeks severe graft-versus-host reaction appeared [147]. Therefore, such mice can 
be used only for short-term experiments. Other model system exploited trans-
plantation of CD34-positive human hematopoietic stem cells into NSG mice and 
demonstrated the establishment of a humanized PDX model with hematopoietic 
restoration [148]. In addition, Morton and colleagues demonstrated that CD34-
positive cells isolated from patient and injected into mouse blood successfully 
restored a functional immune system mimicking that of the patient [149]. Such 
PDX are invaluable for cancer immunology and immuno-oncology drug research. 
Nevertheless, the time required generating enough tumor material in sufficient 
number of mice, as well as patient survival, is of utmost importance for personal-
ized medicine application. Time is the main obstacle impeding the extensive use of 
mouse PDX models, because right drug for the right patient must be given at a right 
time. Development of an individualized PDX takes anywhere from 3 to 6 or even 
12 months, and in many instances, this time is too long, as in the case of metasta-
ses, patients may not even survive PDX creation time. Therefore, this method is 
restricted to patients with a less aggressive disease development.
In addition to that, long time needed to generate sufficient number of mice with 
the same tumor brings another problem—clonogenicity. Research showed that all 
PDX models studied experienced moderate drifts or even dramatic clonal selections 
even within the first mouse passage [150]. Due to selection of preexisting minor 
clones, authors observed rapid accumulation of copy number alterations (CNAs) 
during PDX passaging. Particular CNAs acquired during PDX passaging differed 
from those obtained during tumor development in patients. Some CNAs observed 
in primary tumors later disappeared in PDXs [151]. The results showed that PDXs 
were not static and underwent mouse-specific tumor development: PDX that 
originally had mirrored particular disease after some time changed into the form 
that did not anymore.
Financial aspects are also to be assessed. PDX models are costly as it takes 
much time to create PDX, while immunodeficient mice in addition are expensive. 
Furthermore, PDXs may have limited use in diagnostics due to their low-throughput 
character: they are restricted to test a few agents due to insufficient number of 
animal colonies with individual patient’s tumor. However, it is still important for 
drug validation, biomarker development, and drug resistance analysis.
Other animal models exist; however, those may not meet the requirements 
for personalized medicine and will not be reviewed in detail here. Among others, 
cell line-derived xenografts did not reflect the complexity of tumor heterogene-
ity and displayed pronounce genomic differences compared to relevant tumor 
[152, 153]. Genetically engineered mouse models (GEMMs) carry mutations in 
genes of interest; however, generation of mutant mice carrying several genetic 
Tumor Progression and Metastasis
18
alterations is time-consuming, and complex activation of genetic alterations 
reduces the attractiveness of the method [154]. Besides, GEMMs may not be able 
to mirror the personalized therapy as they have less heterogeneity due to only a 
few genes modified.
4.2 2D in vitro models
Many reviewers have argued that conventional cancer cell lines in a usual 2D 
culture were an oversimplified model to study cancer. Various studies have demon-
strated that both molecular and functional parameters were different depending 
on cell culture conditions, including substrate dimensionality as well as the method 
by which it was created, leading to inconsistent data [155]. Alternatively, primary 
cell-derived 3D spheroids demonstrated different response to therapeutic drugs 
when compared to spheroids from long ago established breast cancer cell lines 
[156]. Growing body of evidence demonstrated that cancer cells growing in 3D or 
2D environment possessed different susceptibility to anticancer treatment, showing 
either increased or decreased sensitivity to apoptosis-inducing agents [157, 158]. 
Therefore, the natural question which models for cancer research should be aban-
doned is very relevant [159]. Regarding cancer cell lines, in general, it is well known 
that they are unstable and possess genetic drift. Long-term cultivation causes other 
problems resulting in poor reproducibility of the results [160–162]. For example, 
a widely used glioblastoma cell line U87MG was found to be completely different 
from the original donor, as DNA profiling revealed [163], many other cell lines were 
misidentified or contaminated [164]. Due to such obstacles, cell line stability and 
bioproduction are the headache for pharmaceutical companies which try to comply 
with strict regulations of healthcare manufacturing.
Nevertheless, these cell lines proved to be useful in basic and fundamental 
molecular biology research, e.g., in studying molecular action mechanisms of 
anticancer drugs, as reviewed many times elsewhere. Easy handling, homogeneous 
character, limitless growth, and high-throughput made it the model of choice for 
many years.  After a lot of criticism from more advanced cancer modeling experts, 
surprisingly, they suddenly appeared to be equally valuable for translational cancer 
research. For example, in a large-scale study summarizing data from the analysis of 
1000 cancer cell lines, their response to 265 anticancer drugs, and 11,000 patient 
samples of 29 different tumor types, authors concluded that a majority of molecu-
lar abnormalities found in tumors including driver mutations were also found in 
cancer cell lines. Furthermore, the results suggested that cell lines could predict 
drug response of a tumor [12]. Earlier, by application of computational methods, 
cell line gene expression profiling and annealing with known pharmacological pro-
files of anticancer drugs successfully predicted unknown drug sensitivities [165]. 
Such methodology may be compared to target-based drug discovery approach. 
However, an alternative approach—agnostic phenotypic screening—has resulted in 
the discovery of majority of first-in-line drugs, and authors noticed the resurgence 
of sophisticated, high-content phenotypic screening. By testing the unlimited 
number of ex vivo cancer cell lines with large libraries of chemicals or biologicals, 
there is a chance of having a significant hit [166, 167]. The NCI-60 panel was 
the first widely used cancer cell line panel in drug discovery. By demand, their 
genomes have been sequenced in 2012 [168]. Today, there is a Human Glioblastoma 
Cell Culture (HGCC) resource that consists of a biobank of 48 cell lines represent-
ing all molecular subtypes of the disease, with an associated database containing 
high-resolution molecular data [169]. Similar work was done with 100 ovarian can-
cer cell lines to make an OCCP panel where the cells were described [170]. Cancer 
Cell Line Encyclopedia (CCLE) and the Cancer Genome Project (CGP) have served 
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well in identifying novel biomarkers in drug response. Recently, large collaboration 
efforts expanded the characterizations of CCLE to include genetic, RNA splicing, 
DNA methylation, histone H3 modification, microRNA expression, and reverse 
phase protein array data. These data were collected for 1072 cell lines of various lin-
eages from individuals of different ethnicities to improve the understanding of the 
molecular features that contribute to cancer phenotypes, including drug responses. 
Computational integration of these data with functional characterization such 
as drug sensitivity, short hairpin RNA knockdown, and CRISPR-Cas9 knockout 
data revealed potential targets and associated biomarkers for further analysis. This 
information is publicly available [171]. Similarly, immortalized cell line models 
such as EBV-transformed lymphoblastoid cell lines (LCLs) from the International 
HapMap Project, Human Variation Panel, and 1000 Genomes Project with mul-
tiomics data became available for fundamental cancer research [172].
Various specific cell lines are created for scientific research. HAP1 is a semi-hap-
loid human adherent cell line derived from the male chronic myelogenous leukemia 
cell line KBM-7, with a single copy of almost every human chromosome. These cells 
are easy to culture, and authors assert that such cell line is an invaluable tool for 
gene functional testing and drug discovery by facilitating gene-editing techniques 
[173]. The well-known resources of cell lines for research and commercial applica-
tions include ATCC, JCRB, and other cell culture biobanks with many species 
covered. The European Collection of Cell Cultures ECACC (UK) offers more than 
1500 human iPSC lines, 450 monoclonal antibody-producing clones, and many 
normal tissue and cancer cell lines for disease modeling or bioproduction [174].
The first attempt to solve the disadvantage of cell line “purity” as well as per-
sonalization of the treatment approach was the introduction of primary ex vivo 
cancer cell lines into the cancer research, including drug testing, discovery and 
therapy response prediction, with improving methodologies and optimizations 
for cell culturing [175–178]. Heterogeneity found in cell cultures was suggested 
to be coded by biological mechanisms from the primary tumors, and it was 
acknowledged as an instrument for clinical implications. Some authors denied 
the global inadequacy of translating pharmacogenomic data from 2D to clinical 
settings suggesting that drug resistance was mainly intrinsic and did not depend 
on cell culturing conditions [179]. However, this question is controversial, as 
other authors demonstrated that DNA methylation profile rapidly changed when 
cells had been plated in vitro, namely there was a global loss of 5hmC modifica-
tion in vitro [180]. In addition, there are also challenges at cellular level. In many 
reports, ex vivo cancer cell line generation often was not 100% effective, meaning 
that obtained cells did not proliferate sufficiently or at all. Too long time frame 
from biopsy to sufficient cell number (2–6 months in lung cancer) [7, 15] is not 
applicable in clinics as well as there is a risk to select only the fast-growing cells, 
the subclones that do not resemble the original tumor; moreover, in many cases, 
patient survival may not be that long. Nevertheless, authors suggested that drug 
screening may be done using fresh cells, or primary cultures, within days while 
still in the presence of stroma cells [73]. Additionally, the issue of cell line genera-
tion and expansion could be solved by advances in culture medium composition, 
cell isolation, passaging, and associated techniques, or by means of assisted cell 
expansion described in [181] which is favorable in the aspect that it also worked 
with normal cells from the same tissue. Briefly, they used human mammary and 
prostate epithelial cells from fresh and even frozen biospecimen using an irradi-
ated feeder cell layer and a Rho kinase inhibitor Y-27632 in the culture medium 
and expanded the culture to 1 million cells in 7 days. In this way, both drug 
screening and toxicity studies can be carried out for the patient simultaneously 
in several weeks. Alternatively, recent advance in cell imaging (next-generation 
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phenotypic screening) may enable fast, miniaturized, and physiologically 
relevant analysis of fresh ex vivo cells in suspension within hours after sample 
acquisition (e.g., IntelliCyt iQue Screener). For adherent cells, various automated, 
high-throughput imaging platforms, such as Cellinsight, ImageXpress Micro, 
Celldicoverer, MACSima, IncuCyte, etc., are available.
Additional pro for ex vivo cell cultures is the evidence of cancer stem-like cells in 
such cultures [91, 182, 183] and similar molecular profiles to those of in vivo cancer 
cells [184]. The latter study suggested that only several existing breast cancer cell 
lines, namely BT483, T47D and MDAMB453, had satisfactory similarity to molecular 
pattern of tumors. Another report supplemented the study by stating that primary 
ovarian cancer cells also differed from the established cell lines in tumor-associated 
antigen expression (namely BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/
neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, 
MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, and WT1 mRNAs), but 
one cell line—OVCAR-3—was quite representative [185]. On the other hand, there 
is evidence that even in common commercial cancer cell lines established long time 
ago and being deposited in biobanks such as ATCC, putative cancer stem cells are 
present [186].
Up to this paragraph, the cell line model has been discussed. However, cells 
growing in monolayer lack typical interactions that are present in tumors. It was 
shown that cell cultivation in 2D and 3D cultures results in different cell morphol-
ogy, intracellular signaling, proliferation rate, differentiation capacity, and thus 
different response to treatment. For example, PDGFR activity was significantly 
lower in three sarcoma cell lines grown in 2D than in spheroids; in addition, stem 
cell markers Nanog, Oct4, and Slug as well as EMT proteins Snail, Slug, and Zeb1 
were significantly higher in spheroids [187]. Another study showed that differ-
ent cytotoxic compounds retained their ranking both in 2D and 3D cultures; 
however, all the IC50 values were smaller in 3D spheroids [188]. As described 
by an example of anti-HER2 targeted drug trastuzumab in a beautiful review by 
Sokolova et al., HER2 formed heterodimers with HER3 in a monolayer culture, 
but in spheroids, HER2 homodimers prevailed; therefore, a greater antiprolifera-
tive effect of this antibody against spheroids in comparison to a monolayer was 
observed. Importantly, HER2/HER2 receptor led to activation of MAPK signal 
transduction pathway, whereas HER2/HER3 receptor activated alternative PI3K 
pathway. Another effect of dimensionality was changes in expression and the basal 
phosphorylation level of cell-surface receptors. It could be either higher or lower in 
3D than in 2D [189]. Similarly, remarkable differences were observed in pancreatic 
cancer cell lines HPAF-II, HPAC and PL45 when cultivated on 2D or 3D [190]. 3D 
hepatocyte spheroids (named as human liver microtissues) have demonstrated 
better prediction of liver toxicity than two-dimensional primary human hepa-
tocytes model [191]. Similarly, large-scale pharmacological profiling of PANC1 
human pancreatic cancer and SN12C human kidney carcinoma cell lines in both 2D 
and 3D was performed, analyzing a collection of 1912 chemotherapeutic agents. 
Interestingly, comparison of pharmacological responses of cells cultured in tradi-
tional 2D monolayer conditions as well as responses obtained from cells forming 
spheres versus cells already in 3D spheres enabled the identification of those key 
signaling pathways and cellular processes that when modulated by drugs were able 
to reduce cancer cell viability in all growth conditions or, to our particular inter-
est, selectively in the different cell growth modes [192]. Thus, 3D culture systems 
comparing to 2D cultures have more advantages for using them for drug investiga-
tion studies. Some of the disadvantages of 2D models were reduced by introducing 
3D substrates, scaffolds, and extracellular matrix components, including well-
known Matrigel. Such models may be placed between 2D and 3D, sometimes called 
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2.5D. Consequently, commercial cell lines or cells isolated from donor tissue can be 
used in cancer research.
Dimensionality alters cellular surface area for a drug to penetrate. On a porous 
scaffold, surface area of a cell may increase; however, in a compact spheroid, 
surface area may decrease when compared to that of a planar 2D adherent cell. 
One study described generation and properties of multicellular tumor spheroids 
from different pancreatic cancer cell lines. Briefly, large and dense spheroids 
represented type I, lose and of different sizes—type II, and floating monolayer 
films—type III. The three types displayed different expression of adhesion mol-
ecules E-cadherin, DSC, and DSG proteins; in addition, type I spheroids had 
higher resistance to doxorubicin and gemcitabine [155]. More importantly, cell-cell 
and cell-surface contacts generate intracellular signaling that has been reviewed 
elsewhere.
Despite the abovementioned in defense of cell cultures, other authors argue that 
in principle the approach is defective in one additional aspect—enzymatic digestion 
of a solid tissue/tumor. This procedure is almost absolutely necessary in generat-
ing cell cultures. However, the proteolytic enzymes (trypsin, collagenase, dispase, 
accutase, etc.) cleave both proteins of the extracellular matrix and cell-surface 
receptors. By doing that, digestion irreversibly changes cellular signaling [193]. 
However, comparison of different cell-dissociating agents for stem cell isolation 
from glioma tumorspheres revealed that there was a difference in CD133 antigen 
retention: the worst result was obtained for nonenzymatic dissociation solution 
NECDS, while the minimal impact was observed in Libertase-TL-treated cells [194]. 
On the other hand, disruption of cell-cell contacts during the initial steps of cell 
culture establishment favors the outgrowth of specific cells, the composition of 
which do not recapitulate the original heterogeneity of a tumor [177]. Therefore, 
organotypic tumor slices without application of proteolysis would be the best model 
for drug selection in the individualized cancer treatment, and it will be discussed 
here below. In addition, tissue slice generation time can be fast enough to receive the 
results in days.
4.3 3D in vitro models
Phenotypic screening-based drug discovery should rely on 3D models because 
monolayer culture cell concentration is strikingly low (105–106 in mL) when com-
pared to in vivo tissue (40–50 million cells in a mL) [195]. However, this recommen-
dation is not attributable to leukemia cell cultures where physiologically relevant 
concentration of the cells can be obtained in vitro for the research. Advances in 
cancer modeling were nicely reviewed in publications [25, 30, 89, 145, 177, 189, 196, 
197]. In our previous publication [198], 3D drug testing models with end-point 
viability-measuring methods were presented, including scaffold-based 3D culture 
systems, tissue slices, cellular spheroids, organoids, and organs-on-chips. Having 
both models for normal tissues and a tumor from a single patient would improve the 
prediction of systemic toxicities to healthy stem cells. As covered by other authors, 
self-organized and stem cell-derived three-dimensional human organoids give 
promise to be applied in disease modeling, drug screening, regeneration therapy, 
and even for host-microbe interaction studies [199]. These models can be patient-
specific and thus are suitable for personalized medicine. When generated from 
cancer patient cells, such organoids have the value in anticancer drug screening 
[200]. More frequently used 3D culture models of cancer include: tumor mono-cell 
spheroids, hetero-spheroids (tumoroids), tumor tissue explants, and tumor-on-
a-chip. 3D printing, to our opinion, is more relevant to nongenetic pathologies 
where normal organ-like structures have to be replicated. Tumor, as known, is of 
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irregular, chaotic structure; thus, there is nothing to reconstruct with a precision of 
a 3D printer. One more three-dimensional approach is the application of decellular-
ized cadaver organs. For example, rat lungs have been used to determine human 
adenocarcinoma cell lines H358, PC9, and SW1573 proliferation on the scaffold, 
cell viability over the culture period and in response to treatment with cisplatin or 
Erlotinib. A resazurin-based reagent was perfused through the scaffold to evaluate 
cell number [201].
Multicellular tumor spheroids represent aggregates of cells formed in conditions 
where cell-cell interactions predominate over cell-substrate interactions. Spheroids 
closely resemble avascular primary tumors and metastases with respect to their 
architecture, gradient of oxygen, nutrients and metabolites distribution, distinct 
proliferation rates as well as microenvironment and drug penetration [202, 203]. 
One-cell-type spheroids are cellular aggregate formed by one type of cells, in this 
case cancer cells. In principal, this type of spheroids can be used as a model system 
for primary avascular tumor or metastasis [204]. Enhanced expression of stem cell 
markers and drug resistance in sphere-forming nonsmall cell lung cancer cells were 
reported: tumor sphere-derived cells expressed stem cell markers CD44, CD133, 
Sox2, and Oct4. Moreover, expression of lung resistance-related protein (LRP), 
glutathione-S-transferase-π (GST-π), and multidrug resistance proteins-1 (MRP1) 
were all significantly enhanced in sphere-derived cells [205]. In addition to spheroid 
formed by one type of cells, more complex multicellular spheroids are used in drug 
studies. This type of spheroids contains not only cancer but also other tumor-
constituting cells, such as fibroblasts, endothelial cell, and immune cell, and thus is 
closer to situation in vivo due to additional cancer-normal cell contacts.
Various techniques can be used to obtain spheroids: plastic culture dishes with 
ultra-low attachment surfaces, spontaneous aggregation under free-floating condi-
tions, liquid overlay on agarose, hanging drop cultures, spinner-flask cultures, and 
micro-fabricated scaffolds [204]. Simplicity in production and use of spheroids has 
led to widespread use of these techniques. Cancer organoids may be created from 
CTCs, as nicely reviewed in [206], highlighting the techniques for CTC isolation 
from patient blood, cell culture enrichment, culture medium supplementation, as 
well as CTC-derived organoid application in disease modeling, genetic instability 
studies, drug discovery, and precision medicine. Interestingly, authors have demon-
strated that replacing fetal bovine serum with human serum could enhance spher-
oid formation and increase the invasiveness of cancer cells in vitro [207]. However, 
not all techniques provide uniform-sized spheroids, resulting in poor reproducibil-
ity of experimental data. Cell biological functionality and sensitivity to drugs have 
a strong correlation with the size of spheroids [208, 209]. The methods of hanging 
drop and microfabricated microstructures enable researches to modulate spheroid 
dimensions but have a limitation for mass production potential and cause difficul-
ties for effective harvesting of spheroids. Recently, a number of optimized spheroid 
production protocols were developed with various robust and effective platforms 
for high-throughput drug screening. Opera Phenix High Content Screening System 
with Synchrony Optics and automated image analysis were reported to be well 
suitable for microtissue spheroid analysis; ImageXpressMicro Confocal automatic 
imaging system with MetaXpress6 software was used for similar purpose.
In a strict sense, the term “organoid” means that the microtissue has originated 
from stem cells that had differentiated in tissue-specific manner and formed a mini-
organ or organ-like structure. Such models of other than oncologic disease research 
have been nicely reviewed elsewhere. However, when microtissue is formed from 
primary cancer cells, some authors call it organoid, and some as spheroid. In either 
way, cancer cells propagated in three-dimensional (3D) culture systems exhibit 
physiologically relevant cell-cell and cell-matrix interactions, gene expression and 
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signaling pathway profiles, and heterogeneity and structural complexity that reflect 
in vivo tumors. In one study, three lines of ex vivo established colorectal tumor 
spheroids were analyzed. All three lines expressed EpCAM, CD133, CD44, CD24, 
ALDH1, and LGR5 biomarkers and maintained them stably for months in vitro. 
STR phenotyping and mutation profile for APC, KRAS, MLH1, serine-threonine 
kinase 11, and TP53 coincided with original tumors from which they had been 
derived [210].
Cancer modeling using organoids was nicely reviewed in [211, 212]; larger 
view on tumoroid application in cancer research was extensively discussed in 
[213]. Patient-derived tumor organoids were suggested as the best model enabling 
high-throughput drug testing in a clinically relevant time frame at the same time 
being cost-effective [23]. Although multicellular spheroids exhibit physiologically 
relevant structural complexity of tumor as well as cell-cell and cell-matrix interac-
tions, smaller than 200 μm spheroids do not reflect the in vivo characteristics of 
tumor cell proliferation, metabolite, and oxygen gradient resulting in necrotic core 
formation. Authors developed an optimized protocol allowing production of large 
spheroids that mimic some of the complex tumor microenvironment, including 
hypoxia. However, in this model, spheroids were unable to develop tumor specific 
vascular architecture, which was achieved by transplanting of spheroids to immu-
nosuppressed mouse .
Another study described a 3D cell culture system to study tumor-stroma interac-
tions in nonsmall cell lung cancer cells by creating mono and co-culture spheroids 
of two NSCLC cell lines A549 and Colo699, and lung fibroblasts. The viability of 
tumor spheroids was determined after 5 and 10 days by using Annexin V/Propidium 
Iodide flow cytometry. Lower viability was observed in A549 monocultures 
compared to co-cultures, whereas Colo699 monocultures showed better viability 
compared to co-cultures. Additionally, tumor-fibroblast spheroid formation was 
characterized by scanning electron microscope, semi-thin sections, fluorescence, 
and immunohistochemistry of E-Cadherin, vimentin, Ki67, fibronectin, cytokera-
tin 7, and a-smooth muscle actin in addition to conventional histology [214].
It is rather difficult to consider which spheroid production method would be 
most suitable for potential drug studies. The main requirement for high-throughput 
analysis is reproducibility of uniform spheroids, as cell susceptibility to therapy 
depends on the spheroid size. It was demonstrated that the size of spheroid may 
depend on production method used, as growing of squamous carcinoma cells on 
ultralow attachment plates resulted in higher proliferation rates and increased 
spheroid size compared to Hanging drop production method. Despite numerous 
spheroid studies, it is not still clear which time point would be ideal to start treat-
ments and evaluate drug response. Typical spheroid structure consisting of an outer 
layer of proliferating cells and inner layer of quiescent cells is detected in spheroids 
larger than 500 μm in diameter. Several agents have been found to be less effective 
in 3D models than in 2D cell cultures due to the drug concentration gradient in 
different layers of spheroid which is relative to drug delivery within solid tumor 
in vivo. Moreover, cell growing in 3D environment showed expression of different 
genes associated with resistance to therapy [205, 215].
Limited drug penetration to the tumor mass is one of the mechanisms which 
determines tumor resistance to applied therapy. This critical parameter is not 
reproduced in monolayer 2D cultures. Meanwhile, spheroids formed from cancer 
cells mimic both the heterogenic multilayer tumor structure and gradient drug 
penetration thus providing more physiologically relevant results as compared to 
monolayer cultures. Cells in the center of spheroid are exposed to nonoptimal drug 
concentrations; thus, increased drug doses or drug combinations are needed to 
provide antitumor effectiveness. Recent studies demonstrated the advantage of 
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spheroid model in evaluating activity of drug combinations and treatment sched-
ules in order to promote drug delivery and accumulation inside a tumor. Therefore, 
spheroid models can be used to assess penetration of different drug formulations.
In drug development, potential agents are further progressed to antitumor 
activity screening in vivo where syngeneic mice model, genetically engineered 
mice models, or xenograft models are used. All these models have some significant 
limitations leading to inadequate results. First of all, tumors are often implanted 
subcutaneously—to the site which does not reflect their original in vivo location. 
Due to the compromised mouse immune system, xenografts are usually character-
ized by higher proliferation rates compared to primary human tumor [115, 216]. 
Moreover, transplanted tumor interacts with stromal components which are not 
of human origin, thus can behave in different manner. Strategy that could signifi-
cantly increase the rate of success would be more complex, physiologically relevant 
cellular models used in early lead discovery. For solid tumors, this would include 
development of 3D in vitro tumor models which recapitulate human tumor archi-
tecture and biology, thus providing greater translational potential [217, 218].
4.4 Complex 3D models
Solid tumors consist of cancer and stromal cells surrounded by extracellular 
matrix. All these cellular and noncellular tumor components co-exist in highly 
interactive 3D environment. Gradient of nutrients, soluble factors, oxygen and 
metabolites occurring in different layers of tumor as well as different type of 
interactions such as cell-cell and cell-ECM regulate cell function and behavior. 
Cancer cells cultivated in 3D environment, if compared to cells growing as a 
monolayer, are exposed to different signals that modify their response to various 
stimuli [158, 219]. For example, cells growing in 3D cultures experience differ-
ent mechanical forces compared to cells growing in 2D. It was demonstrated that 
mechanical properties can regulate cellular response to therapy and angiogenesis 
[220]. Additionally, various interactions occurring in multilayer tumor create 
physical barrier attenuating drug penetration. Recent studies demonstrated that 
3D microenvironment had effect on numerous cellular functions including cell 
morphology, viability, proliferation, differentiation, and migration potential, as 
well as cell signaling, gene and protein expression following response to the applied 
therapy. Taken together, these results indicate that 3D models of cancer provide 
more physiologically relevant results and have greater translational potential to 
successful clinical studies.
There are several artificially engineered 3D cancer models that are close to 
natural tissues and thus partially recapitulate the environment into which a tumor 
cell may invade; for example, three-dimensional organotypic microfluidic model 
to study the phenotype and invasion of glioma stem cells [221]. Artificial skin 
was built of stratified terminally differentiated epidermal compartment of kera-
tinocytes and melanocytes, a dermal compartment of fibroblasts embedded in 
collagen, and a basement membrane deposited by skin cells; such skin reconstruct 
was used for melanoma modeling [222]. Another example is a 3D bone marrow 
model derived from endothelial progenitor cells and multipotent mesenchymal 
stromal cells embedded in alginate and Matrigel. It was used to study immuno-
therapy on primary multiple myeloma [223]. More advanced bone marrow models 
are described in [224] and may involve various soluble factors, osteoblasts and the 
flow of nutrients. Similarly, a lung cancer model named OncoCilAir has almost 
everything that is available in vivo, except immune system of a patient. Briefly, 
OncoCilAir was developed by plating lung fibroblasts and bronchial epithelial cells 
on different sides of a porous membrane. Later, nonsmall cell lung cancer cells were 
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added to the fibroblastic side, and air-liquid interface was introduced to mimic 
the conditions in normal lungs [18]. In that way, OncoCilAir includes both healthy 
and cancerous cells; thus, it can be used to test both tumor-killing activity and the 
adverse effects of anticancer drugs. Moreover, the model could be maintained for 
up to 3 months, which theoretically enables studies of such long-term effects as air 
pollution toxicity, drug resistance, and tumor recurrence.
Organotypic 3D in vitro models are very close to realistic representation of a 
tumor. When a reasonably thin slice of a real tumor is carefully plated on a porous 
surface to ensure better diffusion of nutrients and metabolites, both cancerous and 
stroma cells are present in such a model, including the unchanged intratumoral tis-
sue architecture with ECM and cellular contacts as well as immune cells with natu-
ral cytokines. Such a system is well suited to perform drug selection in personalized 
medicine as it captures the heterogeneity of a tumor, can be multiplexed for various 
biochemical applications, and also is transparent for optical microscopy. Probably 
one of the most advanced commercial systems available today is CANScript from 
Mitra Biotech (India). This platform is intended for prediction of clinical responses 
to anticancer treatment of a certain patient and is applicable in almost all types of 
cancer, including bladder, prostate, HCC, cervical, urogenital, NHL, and GBM. In 
contrast to other similar preclinical models, CANScript and its prediction algorithm 
has been tested in clinical settings for H&N, CRC, breast, pancreas, stomach, 
esophageal, lung, ovarian, AML, and CML cancers [ClinicalTrials.gov identi-
fier (NCT number) NCT03253575]. The technology has been validated in mouse 
xenografts and extremely well correlated with the clinical outcome. Currently, the 
system is being adapted to become an automated platform available to hospitals. 
Briefly, the tumor sample from a patient is cut using a tissue chopper into 200–
400 μm thick slices that are placed into 48-well cell culture plates with RPMI-1640 
medium with supplements including patient blood serum (2%). Importantly, the 
cell culture plate itself is coated with tumor-grade-matched matrix. Tumor-stroma 
matrix proteins (TMPs) are analyzed from the same specimen by mass spectrom-
etry after sample processing, selecting certain proteins to further constitute the 
protein cocktail for plate coating. It ensures the conservation of the tumor micro-
environment in addition to the 3D structure of a tissue slice and native patient-
specific ligands from their blood serum. It was demonstrated many times that the 
mentioned factors determine the fate of tumors in terms of integrity, survival, 
metastasis, and response to chemotherapy. In addition, the CANScript developers 
have demonstrated that explants in noncoated wells lost tumor architecture and 
exhibited decreased viability, proliferation, and activation of oncogenic pathways 
compared with the initial baseline [225]. The method utilizes both morphological 
and biochemical criteria, including measurement of cell viability, ATP utilization, 
proliferation status, changes in tumor area and nuclear fragmentation, activation 
and expression of various signaling proteins by reverse phase phosphoproteomic 
array, immunohistochemistry and qRT-PCR methods for molecular profiling, and 
quantification of biomarkers [17].
However, tissue slicing has some minor limitations. For example, when a tumor 
is larger than the well of a plate into which it has to be positioned, only a portion of 
a slice would be examined. In such a case, the unexamined part of a tumor and its 
response to the suggested treatment could be lost. There are data that drug sensitiv-
ity and biomarker expression vary considerably within individual samples [77, 226]; 
hence, multiple-site samples should be taken, making it difficult for the specialist 
to decide which sites to include in the sampling. Furthermore, cellular signaling and 
hence the drug response in slices may be altered due to suffered mechanical stress 
during the precision cutting and cellular necrosis signaling at the incision planes. 
In addition, it is characteristic to a solid tumor to maintain high interstitial fluid 
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pressure that limits the absorption, e.g., of a drug, and this pressure is not preserved 
in the current models. As noticed by PREDECT team, the ultimate goal—clinical 
application of this method—requires standardization which is impossible in obtain-
ing the samples manually due to different intraoperative manipulation and pathol-
ogy processing even with the same type of cancer [89]. Additionally, for CANScript 
technology, identification and individual plate coating with required TMPs appear 
to be the limiting (expensive and labor consuming) steps, as for these purposes, the 
biopsies firstly have to be analyzed by liquid chromatography-mass spectrometry 
(LCMS/MS), followed by Venn diagrams and heatmaps to select the proteins to be 
mixed in a cocktail for the plate coating.
Another and probably the most straight-forward approach in trying to under-
stand the nature of cancer was the initiative The Cancer Genome Atlas (TCGA), as 
already described above in this review. Starting from 2006, 20,000 primary cancer 
and matched normal samples spanning 33 cancer types have been molecularly char-
acterized, yielding over 2.5 petabytes of genomic, epigenomic, transcriptomic, and 
proteomic data that will remain publicly available at portal.gdc.cancer.gov for the 
research community to use [227]. Comparatively similar problem in data process-
ing is already arising from the next step in cancer modeling that included real-time 
monitoring and gave the fourth dimension for in vitro cancer studies. Apparently, it 
is not applicable in vivo, but definitely it is the future of oncology.
4.5 Single-cell approach
When talking about cancer heterogeneity, we usually think about a complex 
organ-like tumor. That is correct, because human body is mainly solid, and almost 
all cell types form solid tissues. However, blood is liquid and it contains many types 
of different cells; thus, it is also heterogenic. When analyzing blood, we are famil-
iar with flow cytometry and discrimination of cells by their physical parameters 
and CD antigens. The same is for blood cancer: flow cytometry can discriminate 
various subpopulations of abnormal blood cells. Additionally, mass cytometry has 
emerged as a method to evaluate cellular biomarkers on a single cell. Importantly, 
this method has enabled studying the antibody-based cancer therapies as well as 
metal containing chemotherapeutic agents at one-cell resolution [228]. Similarly, 
Western blot method has been miniaturized even to subcellular level [229]. As 
mentioned previously, blood cancer is quite well treated just because there is no 
need for a complex model to study the cell response or resistance to a certain drug 
or combinations. Cells in suspension and can be readily analyzed in vitro not only 
for the antigens, but also for cellular signaling. For example, phospho-flow cytom-
etry was applied in the search for B-cell precursor acute lymphoblastic leukemia 
individualized therapy and enabled to screen for small molecule kinase inhibi-
tors that induced cancer cell death [230]. Functional analysis of single-cell mass 
accumulation rate became available by means of microchannel resonance [231].
Recent technologies have enabled single-cell RNA sequencing thus providing the 
power to dissect intratumoral heterogeneity and to suggest combination thera-
pies [232]. Today, a Phase II clinical trial (NCT01620216) started in 2012 is still 
recruiting leukemia patients for ex vivo drug response prediction. However, even 
here, the microenvironment plays a role. As reported previously, the responses of 
leukemia cells to chemotherapy in vivo, compared to in vitro, were partly related 
to the interactions of leukemic cells and the three-dimensional bone marrow/stro-
mal microenvironment. To investigate this phenomenon, leukemic cell lines were 
co-cultured with human bone marrow mesenchymal stem cell (hu-BM-MSC) in 3D 
and compared to leukemic cells treated in suspension or grown on a hu-BM-MSC 
monolayer (2D conditions) [233]. The authors concluded that cultures in 3D were 
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more resistant to drug-induced apoptosis compared to cells cultured in 2D or in 
suspension.
Further, the modeling becomes complicated when it comes to circulating tumor 
cells (CTCs). During cancer progression, invasive cells evade the primary tumor 
and enter the vascular systems in search for better environment. Such CTCs are 
important in many aspects; the ability to target such cells and to eliminate them 
before the formation of metastasis is of high priority. CTCs are valuable for assess-
ing the profile and heterogeneity of tumor-evading cancer cells. However, their 
direct use as a single-cell model in predicting tumor response to the treatment 
is disputable; therefore, researchers usually create CTC culture models as well 
as mouse xenografts [234]. However, to retrieve CTCs and later to expand their 
culture in vitro is challenging. One study compared three methods (RT-qPCR for 
cytokeratin 19, double immunofluorescence with A45-B/B3 and CD45 antibodies, 
and CellSearch system with CTC kit) to search for and count circulating tumor 
cells in breast cancer patient blood. Interestingly, there was virtually no agreement 
between the methods, including the cancer marker CK19 mRNA-positive cells that 
were also present in 26 healthy female donors [235]. This study demonstrated the 
limitations of biomarker-based cell characterization as well as weakness of technical 
standardization procedures. However, authors described that they have succeeded 
(16.5% success rate) to establish long-term cell cultures from breast cancer CTCs, 
growing them in serum free media supplemented with epidermal growth factor and 
basic fibroblast growth factor under nonadherent, hypoxic conditions [236]. Other 
reports demonstrated that in the case of colorectal cancer, CTC cell line generation 
was possible only from the patients with stage IV cancer and was not successful in 
earlier stages, and the cell cultures demonstrated all the attributes of cancer stem 
cells [182].
In general, pharmacologic response of every single cell from the heterogenic 
cancer tissue should be analyzed whenever possible. In the case of CTCs, single 
cell analysis is very helpful in defining their response to the drugs when cells have 
already escaped from their niche in the tumor tissue, i.e. when cancer cells are 
circulating in pre-metastatic fashion. However, their behavior does not necessarily 
correspond to the response of cells in solid tumor from which they have originated. 
Various microscopy imaging techniques that distinguish individual cells should be 
preferred over pan analysis methods both in vitro and in vivo [237, 238].
5. Upcoming technologies and perspectives
As of particular interest, there are several reports of drug response analysis in 
situ by microinjections into the intact solid tumor, as reviewed in “In situ functional 
diagnostics” [30]. Briefly, the drugs were delivered into the xenograft tumors either 
as a monotherapy compound or up to 16 slowly releasing drug reservoirs, and the 
response was evaluated by retrieving the whole tumor for analysis. Alternative 
approach was used to design acoustofluidic 3D tumor platform to investigate the 
localized release of temperature-sensitive liposomal doxorubicin in glioblastoma 
model [239]. Basically, focused ultrasound raises the temperature in the zone of the 
targeted several square millimeters. When directed at a tumor, such heating favors 
the disassembly of circulating cargo liposomes that contain toxic substances. This 
method shows promise in localized activation/release of chemotherapeutic drugs 
that are not well tolerated in organism and thus fail in dose-escalation trials. One 
more example is a nano device iNANIVID-assisted multiphoton microscopy of indi-
vidual cells when physically inserted into a live solid tissue [240]. This short-term 
(up to 4 h) intravital mouse tumor monitoring was performed in order to validate 
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the nanodevice for drug release; in this particular case, for analyzing EGF-induced 
chemotaxis of metastatic mammary tumor cells. Although this technology seems 
to us not applicable to humans, at least for long-term drug response studies, such 
progress may indicate the evolution of 4D cancer modeling.
Summarizing the above stated, the best cancer model is fully natural tumor in a 
living human. Although it might sound wired, it is true to some extent when talking 
about child cancer in the United States. More than 80% of children who have cancer 
are cured successfully in United States so they are comparatively better served by 
available therapies, as compared to adults. Authors postulate that mainly it was a 
result of incredibly effective chemotherapy combinations that were established 
through highly empirical and incremental clinical trials [241]. However, more tech-
nical approaches may be emerging to advance noninvasive cancer response moni-
toring in a patient to guide the best treatment. For example, magnetic resonance 
methods are able to some extent visualize tumor characteristics and its metabolic 
phenotypes on an anatomical, microvascular, microstructural, microenvironmen-
tal, and metabolomics scale [242]. More specifically, magnetic resonance imaging of 
muscle-invasive bladder cancer revealed that quantification of apparent diffusion 
coefficient (ADC) of water could reliably predict patient response to the neoadju-
vant chemotherapy, i.e., resistant tumors were more heterogeneous in their spatial 
distribution of ADC values [243]. Alternatively, positron emission tomography 
showed promising results in molecular cancer biomarker imaging in vivo by using 
newly developed imaging agents for precise molecular targets. This technique can 
be useful in clinics for measuring early treatment response to predict therapeutic 
efficacy and relating tumor response to survival [244].
The next best thing to the real tumor monitoring in vivo (so-called 4D cancer 
model) is sophisticated 3D in vitro and in vivo mouse models. For fundamental 
studies, light sheet fluorescent microscopy is a new technology for rapid, low photo-
toxicity 3D imaging with resolution similar to that of confocal microscopy; more-
over, super-resolution variations of the method are becoming available. Probably 
the best model in both genetic and physiological relevance, more than a humanized 
mouse, is the putative “patient-on-a-chip.” The model would be comprised of many 
organ-on-a-chip building blocks that presumably would be printed from patient-
derived and differentiated iPSCs, later connecting those blocks in a physiological 
order by microfluidic channels [245]. For example, an array of 3D bioprinted tissues 
(skin, bone and cartilage), microfluidics-based kidney-on-a-chip, lumen forming 
intestine microtissues, and heart model as a multilayer of cardiac fibroblasts alter-
nately layered with iPSC-differentiated myocytes on an elastic silicone membrane 
for efficient beating, are promising components of such a system [246]. However, 
this kind of model is considered only in a preclinical setting for drug research. 
Computational time-lapse movie data analysis also will require the creation of most 
intelligent software [247].
Photo-degradable gelatin may be used for very specific reasons in 3D gel cellular 
models. Using this delicate approach, heterogenous cell cultures may be cultivated 
in one dish until a cell or a colony of interest has to be extracted for analysis, leaving 
the remaining culture intact. This method was used to separate morphologically 
different subpopulations from a murine breast cancer cell line [248]. No digestion, 
no labeling, no flow cytometry is needed.
For 2D cell cultures, noninvasive, time-lapse compatible electrical impedance 
may be used for phenotypic screening, target identification, compound screening, 
lead selection, investigating the mechanism of action, and testing drug safety and 
toxicity [249]. The method also requires gold-plated electrode for cell adhesion.
For single-cell approach, advanced microfluidic techniques are being devel-
oped for multiomics data acquisition in nanodroplets. Briefly, high-throughput 
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single-cell isolation and nucleic acid barcoding methods are making it possible to 
measure the (epi)genomic, transcriptomic, or proteomic state of individual cells by 
elegant strategies and techniques described in [250]. Single-cell methods comple-
mented with gene-editing technologies were recognized among the most perspec-
tive models for disease modeling [159]. Furthermore, a new technology directed at 
cellular spheroid generation using microwells that are much smaller than a well of a 
1536-well plate may be paving its way. The method involves limiting dilution prin-
ciple within traditional 2D cell culture plates coated with polydimethylsiloxane. The 
advantage of this method over traditional limiting dilution is that the small volume 
of a well limits diffusion of autocrine factors and improves extracellular survival 
signaling; at the same time, there is no danger of evaporation. Moreover, many 
clones (300 and more) and other types of cells from a heterogenous cancer tissue 
may be present in the same culture medium allowing paracrine signaling without 
complex microfluidic connections [251] or in a microchip format as developed 
earlier [252].
6. Concluding remarks
Regardless of the abundance of approaches and various models and methods 
developed, the question remains, which models are the best to assess cell hetero-
geneous response to anticancer treatment and to evaluate its clinical relevance? 
Recently, authors have performed SWOT (strengths, weaknesses, opportunities, 
and threats) analysis of 3D cell models and suggested that more transparent 
assessment of the value of new 3D models was needed. Currently, it looks like many 
popular 3D models have no standardized protocols for validation in clinics as well as 
they are not convenient enough, do not mimic cancer biology sufficiently, and thus 
are not suitable for use in clinic. As a result, early enthusiasm regarding 3D models 
is already followed by disillusionment and disappointing results. Development of 
long-term, low-throughput, inconsistent, and expensive models should be aban-
doned for clinical applications; however, such models may have merit in fundamen-
tal research [253].
We suggest that the best model would be simple, miniaturized, inexpensive 
and, at the same time, multifaceted, involving ex vivo analysis of individual cells 
in different states and in different conditions—suspension, 2D and 3D as well 
as co-cultures with stroma cells. Drug screening in such a model would require 
knowledge of which cellular states survive the specific treatment and, according 
to that, combinational therapy—not only by content but also organized in time 
and sequence—should be tested in the model system. The short-term cultivation 
in vitro should be complied for to preserve the patient-specific cellular heterogene-
ity, cell differentiation status, and molecular profile. For this particular reason, 
as well as for the ability to recheck the obtained results, patient’s tumor specimen 
freezing protocols should be developed.
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